TYK2 Inhibitor Deucravacitinib up for FDA Review for Psoriatic Arthritis

Published Date: 07 Aug 2025

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.

Read Full News

Latest News

Early Anti-TNF to Prevent Difficult-to-Treat RA Gains Steam

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy Victoria Johnson

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control Victoria Johnson

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Todays Updates

Can MRI Curb Chemo Overtreatment in Breast Cancer?

MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

New Gene Therapy Nears EU Nod for Bladder Cancer

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.

Latest News

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

News All Time

5 Rheumatology Headlines You Missed in November 2025 Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

This Year in Medicine 2025: Recognizing Top Advances in Healthcare HCPLive Editorial Staff

Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles Chelsie Derman

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial Alex Hillenbrand

A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.

High Rates of Overactive Bladder Found in Women With Fibromyalgia Chelsie Derman

Evidence shows fibromyalgia patients face higher overactive bladder rates and symptom severity, highlighting the importance of integrated care.

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD Chelsie Derman

Multicenter study shows patients with both CKD and gout achieve better urate control on febuxostat than those with gout alone, despite the lower doses.

Unilateral Adrenalectomy for Primary Aldosteronism Linked to CKD, Gout Risks Chelsie Derman

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief Abigail Brooks, MA

In a phase 3 trial, the first-in-class triple agonist delivered up to an average of 71.2 lbs weight loss and reduced WOMAC pain scores for knee osteoarthritis.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout Chelsie Derman

Patients with gout frequently experience kinesiophobia and central sensitization, which were independently linked to greater pain intensity.

taVNS Reduces Pain, Improves Mood in Fibromyalgia Patients Chelsie Derman

New research shows both left and bilateral taVNS are safe, noninvasive treatment options that relieve pain in individuals with fibromyalgia.

GLPG3667 Meets Primary Endpoint in Dermatomyositis, Misses in SLE Phase 3 Trials Alex Hillenbrand

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

Dietary Diversity With Dairy, Fruit, Grains Linked to Lower Gout Risk Chelsie Derman

A large prospective cohort study showed that moderate dietary diversity, particularly greater intake of grains, dairy, vegetables, and fruits, is linked to reduced gout risk.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia Chelsie Derman

Six weeks of freshly squeezed lemon juice diluted in water significantly reduced serum urate and improved kidney function in patients with gout and hyperuricemia.

Rheumatoid Arthritis in 2025: Year in Review Victoria Johnson

The rheumatoid arthritis year in review highlights FDA approvals, data, and advances in 2025.

Fibromyalgia in 2025: Year in Review Victoria Johnson

The fibromyalgia year in review highlights FDA approvals, data, and advances in 2025.

Reframing Fibromyalgia Care in 2025: Restricted Impact of TNX-102 SL’s Approval Philip J. Mease, MD, Nicole Zangoglia, PT, DPT, Andrew Sharobeem, DO, FACR

New advances in fibromyalgia are part of a larger shift in pain management in 2025.

Recommended News For You

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

COVID Lockdowns Significantly Increasing Children's Vitamin D Deficiency?

Early, virtual palliative care feasible for advanced lung cancer

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Many Americans unaware of links between HPV and cancers, poll reveals

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

Asymptomatic or Minimally Symptomatic Myelofibrosis

Recommended Articles For You

The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment  

Understanding Leiomyoma: Causes, Symptoms, and Treatment Options 

Vaccines that can help prevent cancer 

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Canadian Group Calls for Earlier Colorectal Cancer Screening

2.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

3.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

4.

Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.

5.

Research exposes far-reaching toll of financial hardship on patients with cancer

1.

Unlocking the Potential of Cancer Antigen 19-9 for Early Detection

2.

ADCs and Bispecific Antibodies: Advancing the Future of Cancer Immunotherapy

3.

Introduction To Immune Thrombocytopenic Purpura

4.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

5.

Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

5.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot